| pubmed-article:17218636 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17218636 | lifeskim:mentions | umls-concept:C0017296 | lld:lifeskim |
| pubmed-article:17218636 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:17218636 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:17218636 | lifeskim:mentions | umls-concept:C0206681 | lld:lifeskim |
| pubmed-article:17218636 | lifeskim:mentions | umls-concept:C0205065 | lld:lifeskim |
| pubmed-article:17218636 | lifeskim:mentions | umls-concept:C1709313 | lld:lifeskim |
| pubmed-article:17218636 | lifeskim:mentions | umls-concept:C0679199 | lld:lifeskim |
| pubmed-article:17218636 | lifeskim:mentions | umls-concept:C0884118 | lld:lifeskim |
| pubmed-article:17218636 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:17218636 | pubmed:dateCreated | 2007-1-22 | lld:pubmed |
| pubmed-article:17218636 | pubmed:abstractText | Resistance of ovarian clear cell carcinoma (CCC) to platinum-based chemotherapy is associated with poor prognosis, and an effective treatment for advanced disease is urgently needed. HER2/neu is up-regulated more often in CCC than in other histologic types of epithelial ovarian cancer. The purpose of this study was to assess possible treatment for ovarian CCC with the anti-HER2 antibody trastuzumab or human adenovirus type 5 E1A. We treated 10 CCC cell lines with trastuzumab or E1A and assessed cell viability, proliferation, and colony formation and the expression of HER2 and wild-type p53 proteins and molecules downstream of those signaling pathways. HER2 protein was detected at various levels in all 10 cell lines by Western blotting and in 5 CCC cell lines by immunohistochemical staining; HER2 gene amplification was detected (by fluorescence in situ hybridization) in only one cell line (RMG-I). Trastuzumab did not inhibit proliferation in any of the four CCC cell lines tested (RMG-I, SKOV-2, OVTOKO, and OVSAYO). However, transfection with E1A (as compared with control vectors) reduced colony formation in all 10 CCC cell lines regardless of HER2 expression level. Infection of RMG-I and SMOV-2 cells with an adenoviral vector encoding E1A led to significant (P < 0.05) suppression of proliferation and enhancement of cell death; this effect required stabilization of p53 (but not p73) protein and was associated with the up-regulation of Bax and the cleavage of caspase-9. Other mechanisms, such as p53-independent apoptosis, may also be involved in E1A-mediated cell death in CCC. Finally, treatment with E1A prolonged survival in a CCC xenograft model (P < 0.001). E1A gene therapy, because of its ability to stabilize wild-type p53, is worth exploring as a treatment modality for women with ovarian CCC, which typically expresses wild-type p53. | lld:pubmed |
| pubmed-article:17218636 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17218636 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17218636 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17218636 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17218636 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17218636 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17218636 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17218636 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17218636 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17218636 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17218636 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17218636 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17218636 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:17218636 | pubmed:issn | 1535-7163 | lld:pubmed |
| pubmed-article:17218636 | pubmed:author | pubmed-author:KigawaJunzoJ | lld:pubmed |
| pubmed-article:17218636 | pubmed:author | pubmed-author:KanamoriYasun... | lld:pubmed |
| pubmed-article:17218636 | pubmed:author | pubmed-author:ItamochiHiroa... | lld:pubmed |
| pubmed-article:17218636 | pubmed:author | pubmed-author:TerakawaNaoki... | lld:pubmed |
| pubmed-article:17218636 | pubmed:author | pubmed-author:EstevaFrancis... | lld:pubmed |
| pubmed-article:17218636 | pubmed:author | pubmed-author:SneigeNourN | lld:pubmed |
| pubmed-article:17218636 | pubmed:author | pubmed-author:NahtaRitaR | lld:pubmed |
| pubmed-article:17218636 | pubmed:author | pubmed-author:UenoNaoto TNT | lld:pubmed |
| pubmed-article:17218636 | pubmed:author | pubmed-author:Bartholomeusz... | lld:pubmed |
| pubmed-article:17218636 | pubmed:author | pubmed-author:OishiTetsuroT | lld:pubmed |
| pubmed-article:17218636 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17218636 | pubmed:volume | 6 | lld:pubmed |
| pubmed-article:17218636 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17218636 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17218636 | pubmed:pagination | 227-35 | lld:pubmed |
| pubmed-article:17218636 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:17218636 | pubmed:meshHeading | pubmed-meshheading:17218636... | lld:pubmed |
| pubmed-article:17218636 | pubmed:meshHeading | pubmed-meshheading:17218636... | lld:pubmed |
| pubmed-article:17218636 | pubmed:meshHeading | pubmed-meshheading:17218636... | lld:pubmed |
| pubmed-article:17218636 | pubmed:meshHeading | pubmed-meshheading:17218636... | lld:pubmed |
| pubmed-article:17218636 | pubmed:meshHeading | pubmed-meshheading:17218636... | lld:pubmed |
| pubmed-article:17218636 | pubmed:meshHeading | pubmed-meshheading:17218636... | lld:pubmed |
| pubmed-article:17218636 | pubmed:meshHeading | pubmed-meshheading:17218636... | lld:pubmed |
| pubmed-article:17218636 | pubmed:meshHeading | pubmed-meshheading:17218636... | lld:pubmed |
| pubmed-article:17218636 | pubmed:meshHeading | pubmed-meshheading:17218636... | lld:pubmed |
| pubmed-article:17218636 | pubmed:meshHeading | pubmed-meshheading:17218636... | lld:pubmed |
| pubmed-article:17218636 | pubmed:meshHeading | pubmed-meshheading:17218636... | lld:pubmed |
| pubmed-article:17218636 | pubmed:meshHeading | pubmed-meshheading:17218636... | lld:pubmed |
| pubmed-article:17218636 | pubmed:meshHeading | pubmed-meshheading:17218636... | lld:pubmed |
| pubmed-article:17218636 | pubmed:meshHeading | pubmed-meshheading:17218636... | lld:pubmed |
| pubmed-article:17218636 | pubmed:meshHeading | pubmed-meshheading:17218636... | lld:pubmed |
| pubmed-article:17218636 | pubmed:meshHeading | pubmed-meshheading:17218636... | lld:pubmed |
| pubmed-article:17218636 | pubmed:meshHeading | pubmed-meshheading:17218636... | lld:pubmed |
| pubmed-article:17218636 | pubmed:meshHeading | pubmed-meshheading:17218636... | lld:pubmed |
| pubmed-article:17218636 | pubmed:meshHeading | pubmed-meshheading:17218636... | lld:pubmed |
| pubmed-article:17218636 | pubmed:meshHeading | pubmed-meshheading:17218636... | lld:pubmed |
| pubmed-article:17218636 | pubmed:meshHeading | pubmed-meshheading:17218636... | lld:pubmed |
| pubmed-article:17218636 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17218636 | pubmed:articleTitle | Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy. | lld:pubmed |
| pubmed-article:17218636 | pubmed:affiliation | Department of Stem Cell Transplantation and Cellular Therapy, Unit 448, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. | lld:pubmed |
| pubmed-article:17218636 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17218636 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:17218636 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17218636 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17218636 | lld:pubmed |
